Insmed, a Monmouth Junction, N.J.-based biopharmaceutical company focused on inhalants, has appointed Donald J. Hayden, Jr. as executive chairman of the company's board of directors.

Hayden has served as chairman of Insmed’s board of directors since December 2010.  In his new role, Hayden will continue to work closely with Insmed’s president and CEO Timothy Whitten, and the management team, in executing on the development plan for the company's lead product, Arikace (liposomal amikacin for inhalation).  He will also focus more directly on strategic planning and corporate development.

Hayden joined Insmed following the 2010 merger with Transave, where he had served as executive chairman since 2006. Prior to that position, Hayden had a 25-year career with Bristol-Myers Squibb, where he served in key executive roles, including president of global pharmaceuticals, executive vice president and president of Americas, executive vice president of the health care group and several others. Currently, Hayden also serves as lead independent director of Amicus Therapeutics and director of Otsuka Pharmaceuticals. In addition, he serves in board roles for several privately-held companies, including executive chairman of Azelon Pharmaceuticals, chairman of Vitae Pharmaceuticals and Satori Pharmaceuticals and director of Nora Therapeutics.